Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BIOM30001 - Frontiers in Biomedicine > Lecture 20 - Airflow Limitation > Flashcards

Lecture 20 - Airflow Limitation Flashcards

1
Q

List some of the manifestations of atopy

A
  • Allergic rhinitis (hay fever)
  • Eczema
  • Asthma
  • Anaphylaxis
  • Urticaria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the presentations of asthma?

A

Wheezing
Chest tightness
Dyspnoea
Cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the pathological features of the asthmatic airways

A
  • Hypertrophy of smooth muscle in airways
  • Mucous hyper secretion (from goblet cell metaplasia)
  • Inflammatory cell infiltrate into submucosa
  • Vasodilation
  • Thickening of sub epithelial collagen layer
  • Epithelial shedding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Characterise asthma

A

Chronic obstructive respiratory disease

although, individuals can be ‘healthy’ in between episodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the clinical consequences of asthma?

A

Acute inflammation:
• Acute symptoms: bronchoconstriction

Chronic inflammation:
• Exacerbations, non-specific hyper reactivity

Airway remodelling:
• Persistent, fixed airway obstruction
• Significant limitation of airways, even between exacerbations
• Greatly increased work of breathing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the respiratory function tests of individuals with asthma

A

FEV1: ↓↓
FVC: ↓

In obstructive disease, the airway is significantly narrowing, meaning flow through airways is likewise significantly reduced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is dyspnoea?

A

Breathlessness

Recognition of inappropriate degree of respiratory work for body workload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the pathogenesis of asthma

A
  1. Exposure to allergen
  2. Allergen cross-links on IgE bound to mast cells
  3. Activation of mast cells:
    • Degranulation
    • Metabolism of membrane phospholipids
    • Transcription of cytokines

4.
• Recruitment of inflammatory cells
- Neutrophils, eosinophils, Th2
• Goblet cell metaplasia
• Epithelial shedding
• Vasodilation; angiogenesis
• Smooth muscle hypertrophy & hyperplasia
• Subepithelial fibrosis (Collagen deposition)
• Sensory nerve activation → bronchoconstriction (cholinergic reflex, parasympathetic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the consequence of decreased airway diameter?

A

Increased airway resistance →
• Increased work of breathing
• Decreased FEV1
• Airflow limitation (obstruction)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the worldwide burden of asthma

A

One of the commonest chronic diseases

Incidence increasing in developed countries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which factors exacerbate asthma?

A
  • Allergens
  • Respiratory infections (particularly viral)
  • Smoking
  • Irritants
  • Exercise and hyperventilation
  • Weather
  • Emotion
  • Food, drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the process of asthma diagnosis

A 
Lung function tests:
1. Spirometry:
 • Look for airway obstruction:
 • Reduced FEV1 
 • FEV1/FVC ratio <70%
2. Peak flow

Bronchoprovocation test
• Measures airway hyperactivity (AHR)
• Reduction in FEV1 in response to irritants:
• Direct provocation (methacholine, histamine)
• Indirect provocation (exercise, mannitol, hypertonic saline)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the effect of bronchodilators on spirometry in individuals with asthma

A

Bronchodilators can result in improvement in lung function, measured by:
• Increased FEV1
• Normalised FEV1/FVC ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the therapeutic strategy for asthma

A

Therapy aims to minimise underlying pathophysiology:
1. Inflammation
• Preventer therapy
• Glucocorticoids:
- Inhaled (ICS)
- Oral (e.g. Prednisolone, only used in very severe cases)

2. Bronchoconstriction
 • Reliever therapy
 • β2-ADR agonists
- SABAs: used in acute situations
- LABAs: used continuously
 • Relieves symptoms (relaxes airway smooth muscle, improves latency)

Also:
• Combination inhalers (ICS/LABA)
• Leukotriene receptor antagonists
• Anti-IgE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the balance between risk and reward of ICS therapy

A

Reward:
• Relatively low doses sufficient to achieve a considerable clinical improvement (i.e. reduction in inflammation)

Risk:
• Risk relatively low at low doses
• At high doses, infections (e.g. oral candidiasis, thrush) are seen

Thus, at low doses, the reward far outweighs the risk

To minimise the AEs, combination therapy is used:
• Low dose ICS/ LABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

List the commonest combination therapeutics for the control of asthma

A

Serotide

Spiriva

17
Q

What are the main focuses of asthma therapy?

A

Death and severe exacerbations are not seen much any more, due to effective treatment

If day-to-day symptoms and impairment can be controlled, the more significant outcomes (death, severe exacerbations) can also be controlled

This is because control of symptoms is achieved through control of airway inflammation and remodelling

18
Q

What is COPD?

Describe some clinical and epidemiological features

A

Chronic obstructive pulmonary disease
Two conditions:
• Emphysaema (destruction of lung tissue)
• Chronic bronchitis (inflammation and sputum production)

Group of heterogeneous conditions

Progressive, chronic condition

Abnormal inflammatory response to noxious stimuli

Third leading cause of morbidity in Australia (after heart disease and stroke)

Continues to increase in prevalence, unlike CVD, stroke etc.

  • Under-recognised
  • Under-diagnosed (even when respiration is severely impaired)
  • Under-treated
19
Q

What is the major risk factor for COPD?

A

Smoking

In Australia, COPD is almost completely caused by smoking

This is despite the reducing prevalence of smoking in Australia.
The population respiratory effects of smoking and lung cancer take a few years to be realised (20 years)

Other causes are seen in other countries (smoke from stoves)

20
Q

Describe the pathogenesis of COPD

A
  1. Exposure to noxious agent
  2. Inflammation

3a. Small airway disease
• Inflammation
• Remodelling

3b. Parenchymal destruction
• Loss of alveolar attachments
• Loss of elastic recoil

  1. Airway limitation (restrictive lung disease)
21
Q

What is the significance of loss of elastic recoil in COPD?

A

Elastic recoil is endowed by ECM components in the lung parenchyma

This functions to elastically pull on the airways, maintaining airway patency

When the lung tissue is destroyed, the airways tend to collapse

22
Q

What is Dynamic hyper-inflation?

A

Trapping of air in the lungs that cannot be exhaled

Much more common in COPD than asthma

23
Q

Compare the inflammation and consequences thereof in asthma and COPD

A

Asthma:
• Triggered by allergens
• Mast cells and epithelial cells respond
• Eosinophils and Th2 recruited and cause damage
• Results in bronchoconstriction
• Leads to reversible airway restriction

COPD:
• Triggered by chronic exposure to noxious agent (cigarette smoke)
• Epithelial cells and alveolar macrophages response
• Neutrophils and CD8 T cells recruited and cause damage
• Results in destruction of lung parenchyma and small airway narrowing
• Leads to irreversible airway restriction

24
Q

Why is COPD a risk factor for lung cancer?

A

There is shared genetic predisposition for these two things

So, smoking cessation, and thus mitigation of COPD can decrease risk for lung cancer

25
Q

Are asthma and COPD fully reversible?

A

Asthma:
• Yes, through therapy
• Reversible airway limitation

COPD:
• No
• Irreversible airway limitation

26
Q

If one smokes, what is the risk of COPD?

A

Up to 50% of long term smokers will develop COPD

27
Q

Which is the core feature of COPD leading to mortality?

A

Inflammation

28
Q

List the various components of COPD

A 
• Airway inflammation (core component)
 • Airway restriction
 • Mucociliary dysfunction
 • Destruction of lung parenchyma (alveolar tissue)
 • Systemic component:
- Leukocytosis
- Inflammation
29
Q

Describe exacerbations in COPD

A

Present quite similarly to those in asthma

Aetiology:
• Infection (viral, bacterial)
• Air pollution

30
Q

Describe the process of diagnosis of COPD

A 
Evaluation of risk factors:
 • Any past / current smoker
 • Dyspnoea
 • Chronic cough
 • Productive cough
 • Recreational drugs (marijuana, esp. bongs)
 • α-1 antitrypsin (autosomal recessive)
 • Passive smoking
etc.
31
Q

Describe the therapeutic strategy for COPD

A

Smoking cessation is the most important feature
• Biggest factor in prevention
• Leads to most dramatic slowing in acceleration in lung function decline therapeutically

How?

  1. Non-pharmacological
  2. Pharmacological:

Other pharmacological therapy:
1. β2-ADR agonists

  1. Anticholinergics
  2. Inhaled corticosteroids (ICS)
  3. Combination therapy

Other strategies:
• Vaccination (esp. influenza)
• Long term antibiotics

32
Q

What benefit can smoking cessation bring?

A

Before 50 years:
• Resolution of accelerated decline in lung function
• Lost lung function can not be regained
• Most likely won’t progress to ‘disability’ stage

After onset of ‘disability’:
• Slows the rate of decline

If smoking isn’t stopped:
• Onset of ‘disability’ around age 65
• Most likely die due to lung failure at age 70

33
Q

What is classed as lung function ‘disability’?

A

FEV1 <25% value at 25 yrs

34
Q

Describe the use of β2-ADR agonists for COPD therapy

A
  • LABAs for regular use
  • SABAs for symptomatic use
  • Higher doses can lead to reduced QOL (AE: tremor, tachycardia)
35
Q

Describe the use of anticholinergics for COPD therapy

A

• Long-acting, for regular use

Achieves:
 • ↓ Dyspnoea
 • ↑ Exercise tolerance
 • Fewer exacerbations
 • ↓ Mortality
 • AE: dry mouth
36
Q

Describe the use of ICS for COPD therapy

A
  • Inflammation is not such a concern in COPD compared to asthma
  • Neutrophilic inflammation (as in COPD) is ‘steroid-resistant’
  • Benefit demonstrated in severe COPD
37
Q

Describe combination therapy for COPD

A

May achieve:
• Fewer exacerbations
• ↑ QOL
• Improved FEV1

Seretide:
• Fluticase / Salmeterol

Symbicort:
• Budesonide / Formoterol

38
Q

Describe how smoking cessation can be achieved

A 
1. Non-pharmacological
 • Eduction
 • Will power
 • Counselling
etc.
 • Useful in combination with pharmacological therapy, but rarely works in isolation
  1. Pharmacological:
    • Nicotine replacement therapy:
    • Varenicline (Champix)
    • Bupropion
    • These are partial agonists at the nicotine receptor in the brain
    • When one is one these drugs, nicotine does not have its effect in the brain, even if taken

BIOM30001 - Frontiers in Biomedicine (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions